subject area of
- A single institution study evaluating outcomes of PD-L1 high KRAS-mutant advanced non-small cell lung cancer (NSCLC) patients treated with first line immune checkpoint inhibitors Journal Articles
- Alterations of immune response of non-small cell lung cancer with Azacytidine Journal Articles
- An AI-based approach for modeling the synergy between radiotherapy and immunotherapy Journal Articles
- Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC Journal Articles
- Canadian Multicenter Project on Standardization of Programmed Death-Ligand 1 Immunohistochemistry 22C3 Laboratory-Developed Tests for Pembrolizumab Therapy in NSCLC Journal Articles
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma Journal Articles
- Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors Journal Articles
- Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer Journal Articles
- Composite analysis of immunological and metabolic markers defines novel subtypes of triple negative breast cancer Journal Articles
- Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events Journal Articles
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study Journal Articles
- Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer Journal Articles
- Expanded human NK cells from lung cancer patients sensitize patients’ PDL1−negative tumors to PD1-blockade therapy Journal Articles
- FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy Journal Articles
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer Journal Articles
- Fit-For-Purpose PD-L1 Biomarker Testing For Patient Selection in Immuno-Oncology: Guidelines For Clinical Laboratories From the Canadian Association of Pathologists-Association Canadienne Des Pathologistes (CAP-ACP) Journal Articles
- Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors Journal Articles
- How I Do It: Maintenance avelumab for advanced urothelial carcinoma. Journal Articles
- Immune Checkpoint Inhibitors for Patients With Advanced Non–Small-Cell Lung Cancer: A Systematic Review Journal Articles
- Mechanisms of PD-L1 Regulation in Malignant and Virus-Infected Cells Journal Articles
- Nivolumab in Combination With Platinum‐Based Doublet Chemotherapy for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer Journal Articles
-
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (
PD )‐1 orPD ligand 1 inhibitor therapy Journal Articles - Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial Journal Articles
- Pointed Progress in Second-Line Advanced Non–Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition Journal Articles
- Randomized Phase II Study of Durvalumab with or without Tremelimumab in Patients with Metastatic Castration-Resistant Prostate Cancer. Journal Articles
- Recurrent genomic rearrangements in primary testicular lymphoma. Journal Articles
- Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Journal Articles
- TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma Journal Articles
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma Journal Articles
- The efficacy and toxicity of immune checkpoint inhibitors in a real-world older patient population Journal Articles
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline Journal Articles
- “Interchangeability” of PD-L1 immunohistochemistry assays: a meta-analysis of diagnostic accuracy Journal Articles